Maternal and neonatal outcomes associated with treating hypertension in pregnancy at different thresholds
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Lyndsay A Avalos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Northern California Division of Research, Oakland, California, USA. Hauptthemen laut MEDLINE: Pre-Eclampsia, Premature Birth, Hypertension, Pregnancy Complications, Cardiovascular. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Introduction
In the United States, there has been controversy over whether treatment of mild‐to‐moderate hypertension during pregnancy conveys more benefit than risk.
Objective
The objective of the study was to compare risks and benefits of treatment of mild‐to‐moderate hypertension during pregnancy.
Methods
This retrospective cohort study included 11,871 pregnant women with mild‐to‐moderate hypertension as defined by blood pressure (BP) values from three Kaiser Permanente regions between 2005 and 2014. Data were extracted from electronic health records. Dynamic marginal structural models with inverse probability weighting and informative censoring were used to compare risks of adverse outcomes when beginning antihypertensive medication treatment at four BP thresholds (≥155/105, ≥150/100, ≥145/95, ≥140/90 mm Hg) compared with the recommended threshold in the United States at that time, ≥160/110 mm Hg. Outcomes included preeclampsia, preterm birth, small‐for‐gestational‐age (SGA), Neonatal Intensive Care Unit (NICU) care, and stillbirth. Primary analyses allowed 2 weeks for medication initiation after an elevated BP. Several sensitivity and subgroup (i.e., race/ethnicity and pre‐pregnancy body mass index) analyses were also conducted.
Results
In primary analyses, medication initiation at lower BP thresholds was associated with greater risk of most outcomes. Comparing the lowest (≥140/90 mm Hg) to the highest BP threshold (≥160/110 mm Hg), we found an excess risk of preeclampsia (adjusted Risk Difference (aRD) 38.6 per 100 births, 95% Confidence Interval (CI): 30.6, 46.6), SGA (aRD: 10.2 per 100 births, 95% CI: 2.6, 17.8), NICU admission (aRD: 20.2 per 100 births, 95% CI: 12.6, 27.9), and stillbirth (1.18 per 100 births, 95% CI: 0.27, 2.09). The findings did not reach statistical significance for preterm birth (aRD: 2.5 per 100 births, 95% CI: −0.4, 5.3). These relationships were attenuated and did not always reach statistically significance when comparing higher BP treatment thresholds to the highest threshold (i.e., ≥160/110 mm Hg). Sensitivity and subgroup analyses produced similar results.
Conclusions
Initiation of antihypertensive medication at mild‐to‐moderate BP thresholds (140–155/90–105 mm Hg; with the largest risk consistently associated with treatment at 140/90 mm Hg) may be associated with adverse maternal and neonatal outcomes. Limitations include inability to measure medication adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
- Chapman University, Irvine, California, USA.
- Department of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA.
- Kaiser Permanente Southern California Department of Research and Evaluation, California, USA.
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
- Department of Epidemiology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Lyndsay A Avalos
Förderung
- NIDDK NIH HHS
- NICHD NIH HHS
Zitieren
APA
Avalos, L. A., Neugebauer, R. S., Nance, N., Badon, S. E., Cheetham, T. C., Easterling, T. R., Reynolds, K., Idu, A., Bider-Canfield, Z., Holt, V. L., & Dublin, S. (2023). Maternal and neonatal outcomes associated with treating hypertension in pregnancy at different thresholds. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2778
Vancouver
Avalos LA, Neugebauer RS, Nance N, Badon SE, Cheetham TC, Easterling TR, et al. Maternal and neonatal outcomes associated with treating hypertension in pregnancy at different thresholds. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2778
BibTeX
@article{Avalos2023,
author = {Avalos, Lyndsay A and Neugebauer, Romain S and Nance, Nerissa and Badon, Sylvia E and Cheetham, T Craig and Easterling, Thomas R and Reynolds, Kristi and Idu, Abisola and Bider-Canfield, Zoe and Holt, Victoria L and Dublin, Sascha},
title = {Maternal and neonatal outcomes associated with treating hypertension in pregnancy at different thresholds},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2778}
}
EUVIMED